Core Insights - North American Niobium and Critical Minerals Corp. has completed its Phase 1 Fall 2025 prospecting program across four properties in Québec, focusing on verifying historical results and identifying new mineralized trends [1][2][12] Group 1: Program Overview - The 2025 program involved fieldwork from October 13 to November 5, 2025, with a total of 262 grab and channel samples collected, including 94.5 meters of channel sampling on the Seigneurie property [1][2][5] - The Seigneurie property was extended to include a historical REE-anomalous carbonatite subcrop identified by the Québec Ministry of Natural Resources and Forestry in 2015 [2][6] Group 2: Geological Findings - Carbonatite boulders and pegmatite zones were identified across the properties, with significant geological diversity observed, including pegmatites, carbonatites, mafic intrusives, volcanics, metasedimentary units, and gneiss [6][10] - Two carbonatite areas were confirmed: one on the Blanchette property, a newly discovered location, and another on the Seigneurie property, which supports the presence of REE-anomalous carbonatite [7][9] Group 3: Future Outlook - The CEO of North American Niobium expressed optimism regarding the potential of the properties for critical minerals, anticipating assay results that will refine the exploration model for future work [12]

Core Insights - Bread Financial Holdings, Inc. will participate in the Goldman Sachs 2025 Financial Services Conference on December 10, 2025 [1] - The company's President and CEO Ralph Andretta, along with CFO Perry Beberman, will engage in a fireside chat at 1:40 p.m. ET, which will be broadcast live [2] Company Overview - Bread Financial is a tech-forward financial services company that offers personalized payment, lending, and saving solutions to millions of U.S. consumers [3] - The company provides general purpose credit cards and savings products, aiming to empower customers and enhance their quality of life [3] - Bread Financial also supports growth for recognized brands in various sectors through private label and co-brand credit cards, as well as pay-over-time products [3]

Core Insights - Relmada Therapeutics is advancing NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel, into Phase 3 studies for non-muscle invasive bladder cancer (NMIBC) in H1 2026, targeting high-risk and intermediate-risk NMIBC patients, which account for approximately 80% of new NMIBC cases annually in the U.S. [1][2][9] Company Overview - Relmada Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system conditions, with NDV-01 as a lead candidate [10]. Product Details - NDV-01 is designed for bladder retention and gradual drug release over 10 days, enhancing local exposure while minimizing systemic toxicity. It is a ready-to-use formulation that can be administered in-office without the need for anesthesia or specialized equipment [5]. Clinical Study Information - The ongoing Phase 2 study of NDV-01 is an open-label, single-arm trial evaluating safety and efficacy in patients with high-grade NMIBC, with primary endpoints including safety and complete response rate at 12 months [6]. Market Opportunity - NMIBC represents 75-80% of all bladder cancer cases, with a high recurrence rate of 50-80% over five years. With over 744,000 prevalent cases in the U.S. and limited treatment options, the market potential for NDV-01 is significant [9]. Upcoming Presentation - A poster highlighting the 6-month follow-up data from the Phase 2 trial will be presented at the Society of Urologic Oncology 26 Annual Meeting on December 4, 2025 [1][8].

Core Insights - Cognition Therapeutics, Inc. has successfully completed enrollment in its expanded access program for zervimesine, with participants receiving 100 mg daily for up to one year [1][2] - The company has scheduled a Type C meeting with the U.S. FDA for the second half of January to discuss the proposed design of a Phase 3 program for zervimesine in dementia with Lewy bodies (DLB) [2][3] Expanded Access Program - The COG1202 expanded access program is open-label and includes eligible participants from the Phase 2 SHIMMER study and additional patients diagnosed with mild-to-moderate DLB [3] - Dr. James E. Galvin is the lead investigator for this multi-center program [3] Zervimesine (CT1812) - Zervimesine is an investigational oral medication aimed at treating CNS diseases, specifically Alzheimer's disease and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [4] - The drug has shown a good safety profile in clinical studies to date [4][5] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies in early Alzheimer's disease [6]

Core Insights - The global attitude towards alcohol consumption is shifting, with a significant increase in the acceptance of non-alcoholic options during social events, particularly festive seasons [5][6][9] Group 1: Changing Attitudes - A new study indicates that 72% of people feel confident skipping alcohol without fear of judgment [5] - Over two-thirds (67%) believe it is outdated to ask why someone isn't drinking [6] - 81% agree that it is acceptable to decline alcohol at festive events without needing an explanation [6] Group 2: Social Dynamics - The fear of missing out is declining, with 86% comfortable choosing low or no-alcohol options at events [9] - 76% of respondents feel they do not need alcohol to feel included in social gatherings [9] - 90% would support a friend opting for low or no-alcohol drinks during festive seasons [9] Group 3: Generational Trends - Gen Z is leading the movement towards moderation, with 30% planning to alternate between alcoholic and non-alcoholic drinks [8] - The study shows a global trend, with 67% in Brazil and 44% in Japan feeling comfortable choosing non-alcoholic options [10] Group 4: Cultural Shifts - The question "why aren't you drinking?" is becoming irrelevant, with people now using humor to deflect such inquiries [11][12] - Nearly half (46%) associate the holiday season with drinking, but this perception is changing as more people embrace moderation [11] Group 5: Company Initiatives - Heineken® is actively promoting its non-alcoholic beer, Heineken® 0.0, as part of its commitment to social life and moderation [13] - The company emphasizes that choosing non-alcoholic options represents a choice rather than a loss [13]

Core Insights - Capricor Therapeutics announced positive topline results from the Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) [1][2] - The trial demonstrated statistically significant improvements in both skeletal and cardiac function, reinforcing previous findings from the HOPE-2 trial [2][5] - The results are expected to support regulatory approval following a Complete Response Letter from the FDA earlier this year [2][5] Study Details - HOPE-3 was a randomized, double-blind, placebo-controlled trial involving 106 participants across 20 U.S. clinical sites, with an average age of approximately 15 years [2][11] - Participants received intravenous Deramiocel at 150 million cells per infusion or placebo every three months for 12 months [2][12] - The study maintained a favorable safety and tolerability profile consistent with prior clinical experience [2][5] Efficacy Results - The primary endpoint, Performance of Upper Limb (PUL v2.0), showed a 54% slowing of progression compared to placebo (p=0.029) [3][5] - The key secondary endpoint, Left Ventricular Ejection Fraction (LVEF), demonstrated a 91% improvement (p=0.041) [3][5] - Statistically significant results were achieved across all controlled secondary endpoints [5] Clinical Implications - The findings indicate meaningful treatment effects on both upper limb function and cardiomyopathy, addressing critical aspects of DMD [5][6] - The preservation of cardiac function is particularly significant, as cardiomyopathy is the leading cause of mortality in DMD [6][8] - The results provide renewed confidence for families seeking therapies that maintain functional ability and protect heart health [6][10] Company Background - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead candidate for DMD [13] - Deramiocel has received Orphan Drug Designation from the FDA and EMA, along with other designations that may facilitate regulatory approval [10][15] - The company is committed to advancing innovative therapies and has a proprietary platform for targeted delivery of therapeutics [13]

Core Viewpoint - The Magnum Ice Cream Company N.V. (TMICC) has announced the approval and publication of its prospectus for the admission of its ordinary shares to trading on Euronext Amsterdam and the London Stock Exchange, following its planned demerger from Unilever PLC [1][4]. Group 1: Admission and Prospectus - The prospectus has been approved by the Dutch Authority for the Financial Markets and the UK Financial Conduct Authority [1][3]. - TMICC's ordinary shares are set to be listed and traded on Euronext Amsterdam and the London Stock Exchange, with the admission expected to occur on December 8, 2025 [1][4]. Group 2: Demerger Details - The demerger from Unilever is anticipated to be completed on December 6, 2025, with key dates outlined in the prospectus [4][5]. - The latest time for transfers of Unilever shares to be registered is set for December 5, 2025, at 6:00 p.m. London time [6][8]. Group 3: Financial Performance - TMICC is recognized as the world's largest ice cream company, generating €7.9 billion in revenue in 2024 [12].

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinibBased on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a randomized Ph ...

Core Insights - Moomoo has integrated OTC Markets' MOON ATS®, providing 24-hour market access for global investors [1][2][3] - This collaboration addresses the growing demand for extended trading hours, particularly among retail and institutional investors in Asia [2][3] - The partnership enhances Moomoo's offerings, allowing retail investors to trade more flexibly and access global markets regardless of time zones [3][4] Company Overview - OTC Markets Group operates regulated markets for over 12,000 U.S. and international securities, focusing on data-driven disclosure standards [5][6] - Moomoo is a global investment platform with over 28 million users, offering advanced trading tools and insights to empower investors [7][8] - Moomoo has expanded its presence across multiple markets, including Singapore, Australia, Japan, Canada, Malaysia, and New Zealand [8]

First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch WorkshopCARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS) 53rd Annual ...